A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety, tolerability, and PK of MK0683
28 Days
Yes
Medical Monitor
Study Director
Merck
United States: Food and Drug Administration
2008_544
NCT00750178
November 2004
November 2005
Name | Location |
---|